Gerresheimer Gets off to Good Start in New Financial Year

By Gerresheimer Ag, PRNE
Wednesday, April 6, 2011

Group Revenues in the First Quarter of 2011 Rise by 5.2 Percent to EUR 236.6m

DÜSSELDORF, Germany, April 7, 2011 - Gerresheimer AG, one of the leading global suppliers to the
pharma and healthcare industry, got off to a good start in the new financial
year. "We continued on our successful course in the new financial year. We
expect particularly strong growth over the coming years in the emerging
countries. Our latest acquisition of the Brazilian company Vedat strengthens
our position in the emerging markets and expands our product portfolio," says
Uwe Röhrhoff, CEO of Gerresheimer AG.

Cross-reference: Press release including Group Key Figures is
available at

In the first quarter of the financial year 2011 (December 1,
to February 28, 2011) Gerresheimer substantially increased its revenues,
with a 5.2 percent rise to EUR 236.6m. At constant exchange rates the growth
rate was 2.9 percent. The main growth drivers were products like pharma
bottles, injection vials, ampoules, insulin pens and inhalers. There was also
a further rise in demand for cosmetics products.

In the first quarter of 2011 Gerresheimer increased its
adjusted EBITDA to EUR 41.8m, 9 percent up on the prior year. The adjusted
EBITDA margin improved by 0.7 percentage points on the prior year to 17.7
percent. Net income almost tripled to EUR 7.1m in the first quarter. Earnings
per share also improved substantially from EUR 0.06 to EUR 0.20. Net
financial debt was reduced by EUR 84.4m in comparison with the prior year to
EUR 318.2m. In addition, Gerresheimer introduced early refinancing.

"The worldwide demand for medicines will continue to rise in
the coming years. Demographic change, increasing incidence of acute and
chronic diseases, growth of self-medication and the need for healthcare in
the emerging countries will contribute to this. These megatrends provide the
basis for our future growth. With our products and services we can contribute
to improving health and well-being," says Röhrhoff.


For the financial year 2011 Gerresheimer's guidance is that
revenue growth as reported including Vedat will be 7 to 8 percent This is
equiva­lent to revenue growth of 6 to 7 percent at constant exchange rates.
The company assumes unchanged that the adjusted EBITDA margin will reach
around 20%. In 2011 the company expects to invest around EUR 80m.

    Gerresheimer AG

    Benrather Strasse 18 - 20
    40213 Düsseldorf
    Jens Kürten
    Director Corporate Communication & Marketing
    Telephone +49-211-6181-250
    Fax +49-211-6181-241


Jens Kürten, Director Corporate Communication & Marketing, Telephone +49-211-6181-250, Fax +49-211-6181-241, E-mail j.kuerten at

will not be displayed